IBD Patients Treated With Anti-TNF Drug Develop Skin Lesions

IBD Patients Treated With Anti-TNF Drug Develop Skin Lesions
In a new study, researchers investigated the development of skin lesions and their clinical course in patients with inflammatory bowel disease (IBD) who were under anti-tumor necrosis factor (TNF) antibody therapy. The team reported that although skin lesions are a common side-effect of anti-TNF therapy, their severity status rarely requires discontinuation of treatment. The research article, “Characteristics of Skin Lesions Associated With Anti–Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study,” was published in the journal Annals of Internal Medicine. Anti-TNF therapy drugs are used to treat a range of diseases where the production of TNF, an important cytokine of the immune system for the response to infections, is deregulated and its exacerbation causes exaggerated inflammation and onset of disease, such as rheumatoid arthritis and IBD. Anti-TNF drugs including infliximab (Remicade from Celtrion Healthcare), a monoclonal anti-TNF antibody medicine, have proven to be effective in inducing and sustaining IBD remission. Previous studies have reported that some patients with IBD who were treated with anti-TNF therapy developed skin lesions, although the lesions and their clinical course had not been fully described. Now, researchers studied in more detail the occurrence of skin lesions as a result of anti-TNF therapy. The team enrolled 917 patients with IBD who had initiated treatment with infliximab and followed them for a median of 3.5 years. During the follow-up, 214 patients (29 percent) developed skin lesions associated with the use of anti-TNF therapy. Those lesions included psoriasiform eczema (30.6 percent), eczema (23.5 percent), xerosis cutis (10.6 percent), palmoplantar pustulosis (5.3 percent)
Subscribe or to access all post and page content.